India records 27k fresh cases; nod for psoriasis vaccine to treat Covid-19 patients
For the first time in India, a spike of 27,114 fresh cases were reported in the last 24 hours. With this, the national tally reached 8,20,916 cases on Saturday.
As per the Ministry of Health and Family Welfare, there are 2,83,407 active cases in the country and the Indian Council of Medical Research (ICMR) has stated that 2,82,511 samples for Coronavirus – the highest so far – were tested on July 9. In all, a total of 1,13,07,002 samples have been tested in various laboratories across the country.
In another development, the Drugs Controller General of India, Dr VG Somani has approved the Psoriasis injection Itolizumab for restricted use in treating the Coronavirus patients. The approval was given after the clinical trials carried out in India were found satisfactory by a panel of medical experts including pulmonologists, pharmacologists and others from the All India Institute of Medical Sciences (AIIMS).
Apart from this, the experts are weighing the possibility of tuberculosis vaccine limiting the number of fatalities owing to the disease. According to a study, published in the journal Proceedings of the National Academy of Sciences recently stated that in countries where the Bacille Calmette-Guérin (BCG) vaccinations for tuberculosis are administered to children, had lower mortality rate from the disease and India is one of them with 22,123 fatalities so far.
On the global front, India now ranks among the first three nations with a maximum number of cases after the United States of America (32,91,786) and Brazil (18,04,338) taking the global count to 1,26,30,872.